Repros Seeks To Develop Low-Dose Proellex To Avoid Liver Toxicity
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Repros Therapeutics has requested that FDA lift the clinical hold on its uterine fibroid and endometriosis drug Proellex so it can conduct a single clinical trial using several lower doses of the progesterone receptor blocker, the company announced April 5